Search

Theodore E Burnell

from Chattanooga, TN
Age ~58
Get Report
Also known as:
Ted Burnell, Theodore Brunell
Phone and address:
1221 Worthington St, Chattanooga, TN 37405
Related to:
Barry M Burnell, 68Darwyn R Burnell, 89
Connected to:
Allen C Burnell, 64Alyce Burnell, 108Alyssa M Burnell, 34Barbara A Burnell, 83Catherine A Burnell, 66Clifford L Burnell, 45Danny Burnell, 78Deborah M Burnell, 71Edward B Burnell, 60Elaine K Burnell, 77

Theodore Burnell Phones & Addresses

  • 1221 Worthington St, Chattanooga, TN 37405
  • Cleveland, TN
  • Superior, CO
  • Swanton, VT
  • 2432 Bristol St, Louisville, CO 80027 (303) 554-9651
  • Superior, CO
  • Boulder, CO
  • Fishkill, NY

Resumes

Resumes

Theodore Burnell Photo 1

Theodore Burnell

View page
Theodore Burnell Photo 2

Third Party Technical Services Manager At Merck

View page
Location:
Chattanooga, Tennessee Area
Industry:
Pharmaceuticals
Experience:
Merck (Public Company; MRK; Pharmaceuticals industry): Third Party Technical Services Manager,  (April 2005-Present) Manage technical transfer and validation of products manufactured at third party contract manufacturers for Merck (formerly Schering-Plough) Consumer Health Produc...
Theodore Burnell Photo 3

Theodore Burnell

View page

Publications

Us Patents

Alendronate Salt Tablet Compositions

View page
US Patent:
20050181043, Aug 18, 2005
Filed:
Feb 12, 2004
Appl. No.:
10/779050
Inventors:
Indranil Nandi - Plainsboro NJ, US
Pablo Davila - East Windsor NJ, US
Theodore Burnell - Superior CO, US
International Classification:
A61K031/66
A61K009/20
US Classification:
424464000, 514102000
Abstract:
A tablet composition comprising an alendronate salt and optionally one or more excipients, wherein the cumulative total of the alendronate salt particles in the composition have a particle size distribution as follows: (a) about 19% to about 25% of the particles have a particle size of 250 microns as determined by a U.S. Sieve No. 60; (b) about 14% to about 17% of the particles have a particle size of 180 microns as determined by a U.S. Sieve No. 80; (c) about 10% to about 13% of the particles have a particle size of about 150 microns as determined by a U.S. Sieve No. 100; (d) about 16% to about 23% of the particles have a particle size of 90 microns as determined by a U.S. Sieve No. 170; (e) about 9% to about 17% of the particles have a particle size of 75 microns as determined by a U.S. Sieve No. 250; (f) about 13% to about 16% of the particles have a particle size of 45 microns as determined by a U.S. Sieve No. 325; and (g) about 1% to about 10% of the particles have a particle size of less than 45 microns, wherein the weight percents are based on the total weight of the alendronate salt. The tablets do not require lactose or polyvinylpyrrolidone in order to achieve blend uniformity.

Proton Pump Inhibitor Formulation

View page
US Patent:
20030211147, Nov 13, 2003
Filed:
Jun 9, 2003
Appl. No.:
10/458776
Inventors:
Daniel Cullen - Arvada CO, US
Christopher Pelloni - Hatfield PA, US
theodore Burnell - Superior CO, US
International Classification:
A61K009/48
A61K009/54
A61K009/24
A61K031/4439
US Classification:
424/458000, 424/471000, 514/338000
Abstract:
Pharmaceutical capsule dosage forms of benzimidazole proton pump inhibitors are prepared by enclosing one or several enteric coated compressed cores in a capsule shell. The inventive formulations are stable and have higher bioavailability of the active ingredient relative to pellet and granule containing formulations.
Control profile
Theodore E Burnell from Chattanooga, TN, age ~58 Get Report